Clinical trial
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
NCT03233347 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
- Lead sponsor
- Academic and Community Cancer Research United
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 13, 2017
- Completion date
- July 8, 2027
- Enrollment
- 83 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
ann arbor stage i hodgkin lymphoma, ann arbor stage ia hodgkin lymphoma, ann arbor stage ib hodgkin lymphoma, ann arbor stage ii hodgkin lymphoma, ann arbor stage iia hodgkin lymphoma, ann arbor stage iib hodgkin lymphoma, classic hodgkin lymphoma